Abstract
Introduction and Aim. The main categories of drugs employed for medical expulsive therapy in patients with ureteral calculi (UC) are alpha-blockers (α-B) and beta-adrenoceptor agonists. This meta-analysis evaluated the safety and effectiveness of α-B versus mirabegron (MIR) in treating UC.
Methods. From January 1980 to December 2023, we extensively searched the MEDLINE, CENTRAL, and EMBASE databases to identify randomized controlled trials (RCTs) that compared the effectiveness of α-B and MIR in managing UC. Furthermore, a systematic review and meta-analysis were carried out.
Results. The meta-analysis included five publications with 478 patients, comparing α-B with MIR. The stone expulsion rate (SER) was found to be significantly greater in the α-Bgroup than in the MIR group, as indicated by an odds ratio (OR) of 1.64 (95% confidence interval [CI]: 1.11 to 2.43, P = 0.01) in the meta-analysis. However, no significant differences were found between the α-B group and the MIR group for SET (mean difference [MD]: 1.20; 95% CI, -2.71 to 5.10; P=0.55), PE (MD: 0.37; 95% CI, -0.36 to 1.10; P=0.32), or analgesic requirements (MD: 0.79; 95% CI, -0.37 to 1.94; P=0.18). The α-B group exhibited a significantly higher incidence of adverse events compared to the MIR group for orthostatic hypotension (OR 12.16, 95% CI 3.36 to 43.95, P = 0.0001), headache (OR 3.46, 95% CI 1.41 to 8.49, P = 0.007), and retrograde ejaculation (OR 16.30, 95% CI 5.87 to 45.31, P < 0.00001).
Conclusions. Our meta-analysis identified a substantial enhancement in the SER among patients with UC who received α-B therapy instead of those who were administered MIR therapy. Nonetheless, α-B therapy was connected to an increased risk of adverse events.